{"id":"NCT00582426","sponsor":"Novartis Pharmaceuticals","briefTitle":"Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea","officialTitle":"LARCID: Evaluation of Octreotide LAR in Prevention of Chemotherapy-induced Diarrhea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2010-09","completion":"2010-09","firstPosted":"2007-12-28","resultsPosted":"2012-03-27","lastUpdate":"2015-05-04"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Chemotherapy-induced Diarrhea"],"interventions":[{"type":"DRUG","name":"Octreotide Long Acting Release","otherNames":["Octreotide LAR","Sandostatin LAR"]},{"type":"OTHER","name":"Standard Treatment","otherNames":[]}],"arms":[{"label":"Octreotide Long Acting Release","type":"EXPERIMENTAL"},{"label":"Standard Treatment","type":"OTHER"}],"summary":"This study will evaluate the efficacy of Octreotide LAR in preventing chemotherapy-induced diarrhea (with regimens that contain 5 fluorouracil, irinotecan and capecitabine)in patients with colorectal cancer.","primaryOutcome":{"measure":"Percentage of Participants Developing Diarrhea (Grade 1 to 4)","timeFrame":"6 month overall","effectByArm":[{"arm":"Octreotide Long Acting Release","deltaMin":76.1,"sd":null},{"arm":"Standard Treatment","deltaMin":78.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":11,"countries":["Brazil"]},"refs":{"pmids":["24516038"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":68},"commonTop":["Diarrhoea","Nausea","Abdominal pain","Neuropathy peripheral","Vomiting"]}}